MCRB Research and Charts

MCRB - Seres Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-06-04 (Delayed quote data 2025-06-30)

Last 11.11	Change ⇑ +2.01 (+22.09%)	Volume 370,873
	Open 9.03	High 11.58	Low 9.01

8EMA (Daily) 9.15	40EMA (Daily) 7.49	50EMA (Daily) 7.04	STO (Daily) 87.731	MACD Hist (Daily) 0.501
8EMA (Weekly) 8.252	40EMA (Weekly) 4.06	50EMA (Weekly) 3.63	STO (Weekly) 79.594	MACD Hist (Weekly) 0.912


Company Profile
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.